Delve Bio
Bradley Murray is the CEO and Co-Founder of Delve Bio, a biotech company focused on enhancing precision medicine through advanced genomic technology since October 2022. Bradley has also served as an Advisor and Senior Associate at Xontogeny since October 2020. Previously, Bradley worked at Intellia Therapeutics, Inc. from December 2015 to October 2020, holding positions from Associate Computational Scientist to Manager. Earlier experience includes serving as an Associate Computational Biologist at the Broad Institute and an intern at Vertex Pharmaceuticals. Bradley holds a Bachelor of Science in Biology from Georgetown University and an MBA in Finance from Boston College Carroll School of Management.
Delve Bio
1 followers
We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.